JP2021509679A5 - - Google Patents

Download PDF

Info

Publication number
JP2021509679A5
JP2021509679A5 JP2020537571A JP2020537571A JP2021509679A5 JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5 JP 2020537571 A JP2020537571 A JP 2020537571A JP 2020537571 A JP2020537571 A JP 2020537571A JP 2021509679 A5 JP2021509679 A5 JP 2021509679A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
composition according
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020537571A
Other languages
English (en)
Japanese (ja)
Other versions
JP7390294B2 (ja
JP2021509679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/012228 external-priority patent/WO2019136185A1/en
Publication of JP2021509679A publication Critical patent/JP2021509679A/ja
Publication of JP2021509679A5 publication Critical patent/JP2021509679A5/ja
Application granted granted Critical
Publication of JP7390294B2 publication Critical patent/JP7390294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020537571A 2018-01-08 2019-01-03 糖鎖模倣ペプチドを用いて癌を処置する組成物および方法 Active JP7390294B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614956P 2018-01-08 2018-01-08
US62/614,956 2018-01-08
US201862699345P 2018-07-17 2018-07-17
US62/699,345 2018-07-17
PCT/US2019/012228 WO2019136185A1 (en) 2018-01-08 2019-01-03 Compositions and methods of treating cancer with glycomimetic peptides

Publications (3)

Publication Number Publication Date
JP2021509679A JP2021509679A (ja) 2021-04-01
JP2021509679A5 true JP2021509679A5 (cg-RX-API-DMAC10.html) 2022-01-04
JP7390294B2 JP7390294B2 (ja) 2023-12-01

Family

ID=67143977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537571A Active JP7390294B2 (ja) 2018-01-08 2019-01-03 糖鎖模倣ペプチドを用いて癌を処置する組成物および方法

Country Status (6)

Country Link
US (2) US11376307B2 (cg-RX-API-DMAC10.html)
EP (1) EP3737365A4 (cg-RX-API-DMAC10.html)
JP (1) JP7390294B2 (cg-RX-API-DMAC10.html)
AU (1) AU2019205279A1 (cg-RX-API-DMAC10.html)
CA (1) CA3086751A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019136185A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies
CA3185526A1 (en) * 2020-07-28 2022-02-03 Laura L. Eggink Method of treatment of neutrophil-driven inflammatory pathologies
US20230364255A1 (en) * 2020-08-18 2023-11-16 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020715A2 (en) 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US20090246205A1 (en) * 2004-05-13 2009-10-01 Imclone Systems, Inc Inhibition of macrophage-stimulating protein receptor (ron)
KR101652125B1 (ko) * 2007-09-26 2016-08-29 우드라이 파마 게엠베하 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
US8846623B2 (en) * 2010-10-25 2014-09-30 Academia Sinica Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
WO2013096829A2 (en) * 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US20150079071A1 (en) * 2012-11-30 2015-03-19 The Regents Of The University Of California Non-catalytic domain targets in matrix metalloprotease proteins for cancer therapies
GB201300706D0 (en) * 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
US10617755B2 (en) * 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015048477A1 (en) * 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
HUE061339T2 (hu) * 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
US9981044B2 (en) * 2014-08-30 2018-05-29 Susavion Biosciences, Inc. Activation of adaptive immune processes for the treatment of cancers and infectious diseases
WO2016044716A1 (en) * 2014-09-19 2016-03-24 The American University In Cairo Nanoparticle-based combinatorial therapy
CA2971471C (en) * 2014-12-19 2023-04-18 Susavion Biosciences, Inc. Immunotherapy treatments and compositions
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
EP3294887A1 (en) * 2015-05-14 2018-03-21 CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III Mirna compositions for the treatment of mature b-cell neoplasms
US10688153B2 (en) * 2015-11-06 2020-06-23 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
UA125026C2 (uk) * 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
CA3026490A1 (en) * 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Similar Documents

Publication Publication Date Title
Sandhiya et al. The dawn of hedgehog inhibitors: Vismodegib
IL300450A (en) Bicyclic conjugates specific to nectin-4 and uses thereof
Aguiar Jr et al. Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
KR20170117113A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
EP3053578B1 (en) Combination cancer therapy using azabicyclo compound
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
Ma et al. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
TW202228724A (zh) 以反轉錄酶抑制劑治療癌症之方法
CN107801379A (zh) 抗癌剂
EP3735267A1 (en) Methods for treating colorectal and metastatic colorectal cancers
JP2022508935A (ja) がん治療における免疫モジュレーションのための組合せ
CN112584842A (zh) 使用锌剂的肿瘤治疗
Hwang et al. Emerging EGFR-targeted therapy in head and neck cancer: A review
CN119816313A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
Qin et al. CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
US20240277804A1 (en) Triple combination therapy
Takashima et al. Standard first-line chemotherapy for metastatic gastric cancer in Japan has met the global standard: evidence from recent phase III trials
EP4309658A1 (en) Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof
US20230116137A1 (en) Methods for treating colorectal and metastatic colorectal cancers
CN114225023B (zh) 抗csf-1r抗体联合抗pd-l1抗体的应用
Yi et al. Immunotherapy of triple-negative breast cancer
TW202304512A (zh) 雙特異性t細胞銜接體之給藥
Chen et al. Biomineralized engineered Lactococcus lactis-based in situ vaccination enhances antitumor immunity via sequential activation of chemo-immunotherapy
CA3250299A1 (en) CANCER TREATMENT